By Fineline Cube Guangzhou BeBetter Medicine Technology Co., Ltd (SHA: 688759) announced NMPA clearance to initiate a clinical study evaluating ifupinostat (BEBT-908) in combination with CHOP regimen for newly diagnosed peripheral T-cell lymphoma (PTCL). The world’s first approved HDAC/PI3Kα dual-target inhibitor, which received conditional NMPA approval in June 2025 for relapsed/refractory DLBCL, now expands into first-line T-cell lymphoma with a chemo-immunotherapy backbone, leveraging its synergistic dual blockade mechanism to address a high-unmet-need malignancy with limited standard-of-care options.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA) |
| Approval Type | Clinical trial authorization (IND) |
| Product | Ifupinostat (BEBT-908) |
| Drug Class | HDAC/PI3Kα dual-target inhibitor – world’s first approved |
| Combination | CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) |
| Indication | Newly diagnosed peripheral T-cell lymphoma (PTCL) |
| Developer | Guangzhou BeBetter Medicine Technology (SHA: 688759) |
| Prior Approval | Conditional NMPA approval (June 2025) – r/r DLBCL monotherapy |
| Approval Date | 16 Mar 2026 |
Drug Profile & Mechanism
| Attribute | Ifupinostat (BEBT-908) Specification |
|---|---|
| Dual Targets | • PI3Kα (phosphatidylinositol 3-kinase alpha) – core signal transduction kinase • HDAC (histone deacetylase) – epigenetic regulator |
| Mechanism | Synergistic anti-tumor effect through dual pathway blockade: • PI3Kα inhibition: Disrupts tumor cell survival signaling • HDAC inhibition: Modulates gene expression, induces apoptosis |
| Route | Oral administration |
| Approved Indication | r/r DLBCL (conditional, June 2025) – monotherapy after ≥2 prior therapies |
| Confirmatory Trial | Phase III combination with rituximab (second-line+ r/r DLBCL) – ongoing |
PTCL Rationale:
- Aggressive Disease: PTCL carries poor prognosis; 5-year survival <30% for most subtypes
- CHOP Limitations: Standard CHOP achieves only 30-40% complete response; novel combinations needed
- Dual-Target Synergy: HDAC/PI3K blockade addresses T-cell lymphoma biology; potential for enhanced efficacy vs. CHOP alone
Strategic Context & Market Opportunity
| Factor | Implication |
|---|---|
| PTCL Unmet Need | China: 10,000+ annual cases; limited targeted therapies; CHOP remains backbone with poor outcomes |
| First-Line Positioning | Ifupinostat moves from salvage (r/r DLBCL) to front-line (PTCL) – larger addressable population |
| Dual-Mechanism Differentiation | Unique HDAC/PI3Kα combination vs. single-target competitors (brentuximab, pralatrexate) |
| Conditional Approval Strategy | Confirmatory Phase III in DLBCL ongoing; PTCL expansion diversifies clinical risk |
| Pipeline Expansion | Potential for additional lymphoma indications (follicular, mantle cell) and solid tumors |
Competitive Landscape
| Competitor | Product | Mechanism | PTCL Status | Ifupinostat Differentiation |
|---|---|---|---|---|
| Seattle Genetics/Takeda | Adcetris (brentuximab vedotin) | CD30 ADC | Approved (CD30+ PTCL) | HDAC/PI3K dual vs. single target; broader applicability (CD30-negative PTCL) |
| Spectrum/Acrotech | Folotyn (pralatrexate) | DHFR inhibitor | Approved (relapsed PTCL) | Oral convenience; dual-mechanism synergy with CHOP |
| Celgene/BMS | Istodax (romidepsin) | HDAC inhibitor | Approved (CTCL, PTCL) | Adds PI3Kα blockade for enhanced efficacy; combination with CHOP vs. monotherapy |
| BeBetter | Ifupinostat | HDAC/PI3Kα dual inhibitor | Phase II-ready (PTCL) | First approved dual-target; first-line CHOP combination; oral administration |
Development Outlook
| Phase | Timeline | Objectives |
|---|---|---|
| Phase II (PTCL) | 2026-2028 | Efficacy vs. CHOP alone; safety/tolerability; biomarker identification |
| Phase III (DLBCL confirmatory) | 2025-2027 | Rituximab combination; registrational endpoints; full approval conversion |
| Regulatory Strategy | 2028-2029 | PTCL NDA filing; label expansion to other T-cell lymphomas |
| Global Expansion | 2027+ | U.S./EU IND preparation; potential Fast Track for PTCL |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, dual-target mechanism validation, and competitive positioning for ifupinostat in peripheral T-cell lymphoma. Actual results may differ due to combination toxicity, CHOP standard-of-care evolution, and competitive dynamics with novel PTCL therapies.-Fineline Info & Tech